While exploratory and underpowered, the incorporation of machine learning approaches illustrates the feasibility of integrating computational oncology tools into translational biosimilar research, paving the way for future precision-based modeling approaches in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.